138 related articles for article (PubMed ID: 37908176)
1. The efficacy and adverse events of arsenic trioxide for the patients with myelodysplastic syndrome: a systematic review and component network meta-analysis.
Huang X; Liu Y; Liu R; Zou X; Yang H
Hematology; 2023 Dec; 28(1):2274149. PubMed ID: 37908176
[TBL] [Abstract][Full Text] [Related]
2. [Experimental study of the anti-tumor effect of arsenic trioxide or thalidomide alone and combination of both for treatment of myelodysplastic syndrome model].
Lu J; Jin J; Xu WL
Zhonghua Er Ke Za Zhi; 2006 Mar; 44(3):228-33. PubMed ID: 16624066
[TBL] [Abstract][Full Text] [Related]
3. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
Xu SN; Chen JP; Liu JP; Xia Y
Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733
[TBL] [Abstract][Full Text] [Related]
4. A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes.
Wei W; Zhou F; Zhang Y; Guo L; Shi H; Hou J
Leuk Res; 2012 Jun; 36(6):715-9. PubMed ID: 22277680
[TBL] [Abstract][Full Text] [Related]
5. [Mechanisms of arsenic trioxide induced tumor cell apoptosis in myelodysplastic syndrome mice model in vivo].
Lu J; Jin J
Zhonghua Er Ke Za Zhi; 2006 Oct; 44(10):782-6. PubMed ID: 17229386
[TBL] [Abstract][Full Text] [Related]
6. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
Schiller GJ; Slack J; Hainsworth JD; Mason J; Saleh M; Rizzieri D; Douer D; List AF
J Clin Oncol; 2006 Jun; 24(16):2456-64. PubMed ID: 16651647
[TBL] [Abstract][Full Text] [Related]
7. Arsenic trioxide for the treatment of myelodysplastic syndromes.
Vey N
Expert Opin Pharmacother; 2004 Mar; 5(3):613-21. PubMed ID: 15013929
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia.
Chen L; Wang J; Hu X; Xu X
Hematology; 2014 Jun; 19(4):202-7. PubMed ID: 24074286
[TBL] [Abstract][Full Text] [Related]
9. Decitabine shows synergistic effects with arsenic trioxide against myelodysplastic syndrome cells via endoplasmic reticulum stress-related apoptosis.
Huang L; Liu Z; Jiang H; Li L; Fu R
J Investig Med; 2019 Oct; 67(7):1067-1075. PubMed ID: 30898879
[TBL] [Abstract][Full Text] [Related]
10. A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.
Sekeres MA; Maciejewski JP; Erba HP; Afable M; Englehaupt R; Sobecks R; Advani A; Seel S; Chan J; Kalaycio ME
Cancer; 2011 Mar; 117(6):1253-61. PubMed ID: 20960521
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide, thalidomide and retinoid acid combination therapy in higher risk myelodysplastic syndrome patients.
Zheng WL; Zhang GS; Xu YX; Shen JK; Dai CW; Pei MF
Leuk Res; 2008 Feb; 32(2):251-4. PubMed ID: 17920679
[TBL] [Abstract][Full Text] [Related]
12. Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity.
Wu X; Hu Z; Nizzero S; Zhang G; Ramirez MR; Shi C; Zhou J; Ferrari M; Shen H
J Control Release; 2017 Dec; 268():92-101. PubMed ID: 29042320
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug.
Bonati A; Rizzoli V; Lunghi P
Curr Pharm Biotechnol; 2006 Dec; 7(6):397-405. PubMed ID: 17168655
[TBL] [Abstract][Full Text] [Related]
14. Arsenic trioxide as a treatment for myelodysplastic syndrome.
Sekeres MA
Curr Hematol Malig Rep; 2006 Mar; 1(1):34-8. PubMed ID: 20425329
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis.
Wang H; Chen XY; Wang BS; Rong ZX; Qi H; Chen HZ
Leuk Res; 2011 Sep; 35(9):1170-7. PubMed ID: 21774985
[TBL] [Abstract][Full Text] [Related]
16. Curcumin reduces the expression of survivin, leading to enhancement of arsenic trioxide-induced apoptosis in myelodysplastic syndrome and leukemia stem-like cells.
Zeng Y; Weng G; Fan J; Li Z; Wu J; Li Y; Zheng R; Xia P; Guo K
Oncol Rep; 2016 Sep; 36(3):1233-42. PubMed ID: 27430728
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P
J Clin Oncol; 2006 Jun; 24(16):2465-71. PubMed ID: 16651646
[TBL] [Abstract][Full Text] [Related]
18. Acute lung injury induced by arsenic trioxide in a patient with refractory myelodysplastic syndrome.
Hassaballa HA; Lateef OB; Silver MR; Balk RA
J Crit Care; 2005 Mar; 20(1):111-3. PubMed ID: 16015525
[TBL] [Abstract][Full Text] [Related]
19. Retrospective study of arsenic trioxide for childhood acute promyelocytic leukemia in China: a single-center experience.
Wang H; Hao L; Wang X; Li J; Wu Q; Bian S
Int J Hematol; 2010 Jun; 91(5):820-5. PubMed ID: 20461563
[TBL] [Abstract][Full Text] [Related]
20. [The safety and efficacy of low dose subcutaneous decitabine combined with arsenic trioxide in patients with inermediate or higer-risk myelodysplastic syndrome].
Ai H; Wei XD; Yin QS; Mi RH; Chen L; Wang Q; Song YP
Zhonghua Nei Ke Za Zhi; 2019 Dec; 58(12):908-910. PubMed ID: 31775455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]